Activity of ruboxyl, a nitroxyl derivative of daunorubicin, on experimental models of colorectal cancer metastases

Tumor Biology

Volumn 20, Issue 5, 1999, Pages 270-276

  Sirovich, Igor ^a   Konovalova, Nina ^c   Codacci Pisanelli, Giovanni ^c   Volkova, Ludmila M ^c   Giuliani, Andrea ^a   Cicconetti, Franco ^a   Seminara, Patrizia ^c   Mazzocconi, Gualtiero ^b   Franchi, Fabrizio ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Casilino Clinic   (Italy)

^c NONE

Author keywords

Colorectal cancer; Experimental hepatic metastases; Nitroxylated compounds

Indexed keywords

DAUNORUBICIN; FLUOROURACIL; RUBOXYL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; EXPERIMENTAL MODEL; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032810873     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030074     Document Type: Article

References (16)

1. Emanuel NM, Konovalova NP, Diatchkowskaya RF: Toxicity, antitumor activity and pharmacokinetics of spin-labeled thio-TEPA analogs. Cancer Treat Rep 1976;60: 1605-1609.
2. Konovalova NP, Diatchkovskaya RF, Kukushkina GV: Pharmacokinetics of spin-labeled rubomicin analog. Neoplasma 1988;35:185-189.
3. Emanuel BM, Konovalona NP, Diatchkovskaya RF: Potential anti-cancer agents - nitroxyl derivatives of rubomycin. Neoplasma 1985;32: 285-292.
4. Konovalova NP, Diatchkovskaya RF, Volkova L, Varfolomeev VN: Nitroxyl radicals decrease toxicity of cytostatic agents. Anti-Cancer Drugs 1991;2:591-595.
5. Leonetti C, Aronne T, Konovalova NP, Diatchkovskaya RF, Shapiro AB, Franchi F: Ruboxyl, a new nitroxyl derivative of daunorubicin: Acute toxicity and antitumor effect in animals. Int J Oncol 1993;3:615-618.
6. Franchi F, Konovalova NP, Seminara P, Diatchkovskaya RF, Volkova LM, Bonomo L: Ruboxyl as a potential antitumor agent in the therapy of colorectal cancer. Cancer TherControl 1992;2:199-205.
7. Gayowsky TJ, Iwatsuki S, Madariaga JR: Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery 1994;116:703-711.
8. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
9. Jatzko GR, Lisborg PH, Stettner HM, Klimpfinger MH: Hepatic resection for metastases from colorectal carcinoma: A survival analysis. Eur J Cancer 1995;31A:41-46.
10. Sutanto-Ward E, Sigurdson ER, Tremiterra S, Lincer R, Chapman D, Niedawiecki D: Adjuvant chemotherapy for colorectal hepatic metastases: Role of route of administration and timing. Surg Oncol 1992;1:87-95.
11. Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S, Garaci E: Antitumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 1994;57: 701-705.
12. Zinzars N, Leitina BJ, Tumyan BG, Svet-Moldavsky GY: Organ-like formations developing from tissue of the gastrointestinal tract during transplantation. Bull Exp Biol Med 1971;7:81-84.
13. Van Ark-Otte J, Peters GJ, Pizao PE, Keepers YPAM, Giaccone G: In vitro schedule-dependency of EO9 and miltefosine in comparison to standard drugs in colon cancer cells. Int J Oncol 1994;4:709-715.
14. Korman DB, Garin AM, Gershanovich ML, Moiseenko VM, Snimchicov VA, Zharcov SA, Seminara P, Gargano L, Franchi F: Ruboxyl: Phase I trial and clinical perspectives. J Exp Clin Cancer Res 1995; 14:65-70.
15. Rougier P, Douillard JY, Culine S, Sue E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganemn G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15: 251-260.
16. Zalcberg JR, Cunningham D, Van Cutsem E, François E, Schornagel J, Adenis A, Green M, Ivesan A, Azab M, Seymour I for the Tomudex colorectal study group. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996;14:716-721.